Altor BioScience
Altor BioScience is a privately owned clinical-stage biopharmaceutical company focused on treatment of cancers and viral infections using cytokine-based fusion proteins.[1][2] As of 2017 it had raised around $27.8M from investors[3] and around $20M in SBIR grants,[4] and had twelve clinical trials underway.[5] The company was spun out from Sunol in 2002 based on T cell receptor work; Sunol was previously spun out from Baxter in 1996 with the T cell receptor technology and some antibodies.[2][6]
One of its products is ALT-801, which is a fusion protein of IL-2 and a soluble T-cell receptor for p53 tumor-associated antigen (p53 TCR); ALT-801 itself attacks tumors and draws an immune response against the tumor.[2][7]
ALT-802 is a fusion protein combining immunoglobulin G and p53 TCR, and ALT-803 is a fusion protein of IL-15 and the sushi domain of its alpha receptor, which is directly linked to the Fc region of IgG1.[2][8][9] ALT-803 was given fast track status by the FDA in 2017 and at that time, Phase III trials in bladder cancer were being prepared.[1] ALT-836 (formerly called Sunol-cH36) is a human/mouse chimeric monoclonal antibody that blocks the site on tissue factor where factor X and factor IX bind to it, and was in clinical trials to treat acute lung injury and acute respiratory distress syndrome;[10] it was originally developed at Sunol, which licensed it to Genentech, and Altor licensed it in turn.[2][11]
Patrick Soon-Shiong acquired a majority stake in Altor between 2015 and 2017, and in 2017 he attempted to have another of his companies, NantCell, acquire Altor; other shareholders objected to the terms and attempted to block the deal.[1][12] In October 2016 Altor and NantKwest, another Soon-Shiong company, had agreed to explore clinical trials combining each of ALT-801 and ALT-803 with NantKwest's cell therapies against cancer.[13]
References[edit]
- ↑ 1.0 1.1 1.2 Adams, Ben (June 28, 2017). "Altor shareholders revolt against Soon-Shiong buyout". FierceBiotech.
- ↑ 2.0 2.1 2.2 2.3 2.4 Carroll, John (May 4, 2009). "Emerging Drug Developer: Altor BioScience". FierceBiotech.
- ↑ "Altor BioScience Corp. - Company Profile -". BioCentury. Retrieved 30 June 2017.
- ↑ Pounds, Marcia Heroux (October 7, 2015). "Miramar biotech firm awarded research grant". Sun-Sentinel.com.
- ↑ Davis, Jessica (21 June 2017). "NantHealth founder Soon-Shiong hit with lawsuit over attempted takeover". Healthcare IT News.
- ↑ "Optimizing Protein Expression Speaker Biographies - PEGS 2012: Peter Rhode profile". Cambridge Healthtech Institute. Retrieved 30 June 2017.
- ↑ "ALT 801". AdisInsight. Retrieved 30 June 2017.
- ↑ "ALT 803". AdisInsight. Retrieved 30 June 2017.
- ↑ Romano, Emanuela; Margolin, Kim (2017). "18. T Cell Modulatory Cytokines". In Butterfield, Lisa H.; Kaufman, Howard L.; Marincola, Francesco M. Cancer Immunotherapy Principles and Practice. Springer Publishing Company. pp. 277–278. ISBN 9781617052736. Search this book on
- ↑ Leung, K (March 21, 2013). "64Cu-1,4,7-Triazacyclononane-1,4,7-triacetic acid-p-isothiocyanatobenzyl-ALT-836". Molecular Imaging and Contrast Agent Database. PMID 23534079.
- ↑ "ALT 836". AdisInsight. Retrieved 30 June 2017.
- ↑ Montgomery, Jeff (June 21, 2017). "Altor Bioscience Suit Claims Insiders Lowballed Merger". Law360.
- ↑ Adams, Ben (October 4, 2016). "I/O pair Altor BioScience and NantKwest team up for experimental combo studies". FierceBiotech.
This article "Altor BioScience" is from Wikipedia. The list of its authors can be seen in its historical. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
